N. Dickgreber (Hannover, Germany), P. E. Postmus (Amsterdam, The Netherlands)
Lung volume reduction surgery in patients with early-stage lung cancer: a single-center study
D. Lardinois, I. Opitz, E. Grebski, V. Rousson, E. Russi, W. Weder (Zurich, Switzerland)
|  |
Validating lung cancer multi-disciplinary meetings; are decisions being followed?
D. Pandit, J. Mcfadden, K. Srinivasan, H. Moudgil (Telford, Shropshire, United Kingdom)
| |
Clinical study for monochemotherapy of amrubicin, a topoisomerase II inhibitor, in patients with previously treated small cell lung cancer
S. Morita, K. Irisa, T. Sano, T. Yamada, M. Ida, T. Hirata (Shizuoka, Japan)
| |
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
J. Skrickova, M. Tomiskova, A. Svobodnik, B. Kadlec, I. Vasutova, L. Babickova, I. Hanke, T. Horvath, J. Vomela, P. Turcani (Brno, Czech Republic)
|  |
Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy
I. Spasova, R. Pajdlhauser, M. Marel, J. Musil (Prague, Czech Republic)
| |
Dexamethasone improves antiemetic control in lung cancer patients treated with chemotherapy
T. Sarcev, N. Secen, D. Povazan, A. Sabo, D. Bursac, M. Kakas, A. Milovancev (Sremska Kamenica, Vojvodina, Novi Sad, Serbia And Montenegro)
| |
Clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer
M. Kawakami, S. Ohno, A. Tsujita, M. Bando, Y. Sugiyama (Tochigi, Japan)
| |
Does large airway intervention for patients with malignant disease result in early clinical benefit
B. Madden, M. Wilde, A. Sheth, J. Myerson, M. O‘brien (London, United Kingdom)
| |
The estimations of two regimenes of radiation of brain metastases in patients with primary lung cancer
G. Gligorijevic, N. Jovanovic Korda, D. Grujicic (Belgrade, Serbia And Montenegro)
| |
Postoperative adjuvant treatment in stage III NSCLC
S. Adzemovic, D. Subotic, G. Radosavljevic Asic (Belgrade, Serbia And Montenegro)
| |
Gemsitabine plus cisplatine therapy in local advanced NSCLC
B. Komurcuoglu, H. Aydogan, M. Gayaf, E. Yalniz, E. Ozden (Izmir, Turkey)
| |
Zoledronic acid limits experimental malignant pleural effusion
G. T. Stathopoulos, C. Moschos, A. Kollintza, I. Psallidas, H. Loutrari, S. Magkouta, H. Petrocheilou, P. Theodoropoulou, S. A. Papiris, C. Roussos, I. Kalomenidis (Athens, Greece)
| |
Management of outpatients referred to a lung cancer diagnostic clinic
D. Sanchez, F. Andreo, A. Ruiz, J. Roca, E. Monso (Badalona, Catalonia, Spain)
| |
Pathway of lung cancer presentation – does it affect management?
K. Lilley, D. Saralaya, D. Newton, A. Dwarakanath, R. Mustafa, B. Jacob (Bradford, United Kingdom)
| |
Retrospective evaluation of 992 hospitalised malignant patients
A. Ustamujic, H. Zutic, A. Hadziredzepovic, V. Cukic, V. Lovre, I. Sladic (Sarajevo, Bosnia And Herzegovina)
| |
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
I. Gkiozos, N. Katirtzoglou, K. Pantazopoulos, D. Stathopoulos, I. Tzanou, E. Chondrou, A. Zalonis, E. Katirtzoglou, K. Giannopoulos, K. Syrigos (Athens, Greece)
| |
PET scan in stage IA lung cancer
H. Burhan, K. Mohan, P. Littler, J. McShane, A. McIver, M. Ledson, M. Walshaw (Liverpool, United Kingdom)
| |
Three drug regimen in SCLC-ED patients: a phase II study
A. Charpidou, N. Katirtzoglou, I. Gkiozos, C. Alamara, I. Tzanou, K. Dilana, E. Kotteas, I. Tourkantonis, K. Syrigos (Athens, Greece)
| |
Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC)
P. Gudiel Arriaza, T. Gonzalez Budiño, C. Escudero Bueno, A. González Panizo, J. Martinez González Del Río (Oviedo, Asturias, Oviedo, Spain)
| |
The relationship between hemoptysis and the features of tumors in primary lung cancer
F. Sahin, G. Karapinar, M. Bayraktaroglu, D. Görgün, G. Özgül, F. Arkin, P. Yildiz (Istanbul, Turkey)
| |